secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001193125-24-240603
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase closes $110M private placement, up to $275M total, advances IkT-001Pro in PAH
--------------------------------------------------------------------------------

- Gross proceeds ~$110M from private placement; potential aggregate up to ~$275M from warrant exercises.
- Proceeds to fund Phase 2b '702' trial of IkT-001Pro in PAH and for general corporate purposes.
- Appointed four new directors: Roberto Bellini (Independent Chair), Amit Munshi, David Canner, Arvind Kush.
- Resignations of Dr. Paul Grint and Gisele Dion, not due to disagreements; fully vested options paid through Dec 31, 2024.
- IkT-001Pro is oral, potentially disease-modifying imatinib prodrug aiming to improve safety/tolerability in PAH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/d902445d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-240603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer